

## *Why carry out this study?*

- The sustained-release intravitreal fluocinolone acetonide implant (Retisert®; Bausch & Lomb, Inc.) used to treat eyes with noninfectious posterior uveitis can lead to difficulty in controlling intraocular pressure in the postoperative period, leading some glaucoma practitioners to advocate for concurrent glaucoma surgery in vulnerable patients.
- This study was designed as a retrospective series to evaluate the outcomes of Ahmed valve with or without combined simultaneous Retisert implantation in eyes with uveitic glaucoma and to compare the results to Ahmed valve in eyes with primary open angle glaucoma (POAG).

## *What was learned from the study?*

- We found that: (1) Retisert combined with simultaneous Ahmed valve implantation led to significantly longer success compared to Ahmed valve alone in eyes with uveitis or POAG; (2) Retisert combined with Ahmed valve did not lead to significant worsening of glaucoma control as suspected due to prolonged steroid release in uveitic eyes; and (3) eyes with uveitis had significantly better intraocular pressure control and needed fewer glaucoma medications following Ahmed valve than eyes with POAG.
- These data should compel further investigation to elucidate a reason for the differential response between groups, and if validated, would support prospective trials evaluating the expanded use of steroid implants in selected uveitic glaucomatous eyes undergoing drainage device placement.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for this study or publication of this article. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).